Latest European Market Expansion News

Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.

ECS Botanics delivered a fourth consecutive quarter of positive operating cash flow in Q4 FY26, with a full-year turnaround of $5.9 million. The company’s branded B2C revenue surged 31% year-on-year, supported by product launches and European market expansion.

EcoGraf has appointed Sven Olsson as an independent director and Peter Schuhmacher as a board advisor to bolster its European investor relations and advance its HFfree purification technology amid growing ESG demand.

Collins Foods has expanded its German presence by acquiring eight KFC restaurants in Bavaria, increasing its portfolio by 50% and strengthening its growth strategy in Europe.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Bioxyne has locked in a two-year, $50 million exclusive supply agreement with German pharmaceutical distributor ADREXpharma, granting exclusive rights to its Dr Watson® brand in Germany and reinforcing its foothold in Europe’s largest medicinal cannabis market.

Titomic Limited has secured a significant $1.7 million purchase order from the Netherlands’ Royal NLR, reinforcing its foothold in European aerospace and defense additive manufacturing.

Collins Foods is rapidly expanding its footprint in Germany through the acquisition of eight KFC restaurants in Bavaria and an ambitious development plan targeting up to 90 new outlets. Meanwhile, the company refocuses its Netherlands operations with a revamped franchise agreement.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

DTI Group Ltd reported a 33% revenue increase to $5.69 million for the half-year ending December 2025, significantly narrowing its net loss while winning major contracts with Rio Tinto and CAF. The company’s strategic re-entry into Europe and a robust $175 million opportunity pipeline signal a promising outlook.

Argent BioPharma has completed its largest commercial shipment of CannEpil® to Ireland, marking a key milestone in its European expansion with a delivery valued at approximately AUD 783,000. The product is fully reimbursed under Ireland’s National Health Insurance scheme, enhancing patient access for refractory epilepsy treatment.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.